The purpose of this clinical study is to see whether a medical device called the Paradise Renal Denervation System (also called The Paradise System) can lower high blood pressure in participants who are known to have hypertension. The device and the treatment delivered by the device, which is known as renal denervation, are investigational in the United States because they haven't been approved by the FDA. Renal denervation is a procedure where a catheter is placed inside these blood vessels (renal arteries). The ultrasound energy is created when the catheter is connected to a power source known as a generator. The ultrasound energy will heat up a small area of tissue around the blood vessel to disable nerves that are surrounding the blood vessels.
Participants will stop taking hypertensive medication before the procedure and up to two months after the procedure. Participants will be randomized to the procedure or control and will be followed for 36 months. At the six month follow-up appointment, participants will learn whether they had the procedure or not. Those who did not receive the procedure can opt in to have the procedure in the future.
Peripheral vascular interventions are minimally invasive options for the treatment of patients with peripheral arterial disease (PAD). Unfortunately, the effects of this procedure are short-term and there remains a high rate (40-70%) of restenosis (re-narrowing of the arteries). The purpose of this research study is to determine if the use of the catheter for the delivery of the study drug called paclitaxel, will prevent re-narrowing of the blockage of an artery to be treated in the leg.
The purpose of this study is to collect measurements related to the body such as blood pressure, the amount of oxygen in the blood, and heart rhythm recordings. Findings from this study may be used to help design new device-based monitoring technologies in the future.
Continuous blood pressure readings will be obtained during standard of care heart catheterization procedures that include the use of an arterial blood pressure line. Continuous readings of oxygen saturation and ECG will also be obtained. Participants will consist of subjects aged ? 18 years who are scheduled to undergo a cath-lab (cath-lab, percutaneous coronary intervention or equivalent) procedure that includes the use of an arterial blood pressure line.
This is a clinical study looking at the effectiveness and safety of a new device called The Paradise System to use for renal denervation in patients who have mild to resistant hypertension. The goal of renal denervation is to lower blood pressure by using ultrasound waves to heat and disable the nerves surrounding the blood vessels leading to the kidneys. It is believed these nerves may be too active in patients with high blood pressure. The study is divided into two groups, those on one to two anti hypertensive medications (Solo) and those on three or more(Trio). The Trio group will stop their current medication regime and be given one of two combination medications while monitoring their blood pressure. If they continue to meet inclusion criteria, they will be randomized to undergo a renal denervation procedure using the new system versus no procedure. Their assignment will not be made known to them until their six month follow up visit. All groups will be followed up to 3 years but patients who did not initially have the procedure will have the opportunity to have it at a later date.